SABCS 2025

Important new data for young breast cancer patients

Firstline treatment of MBC: Which strategy is best?

Patients contribution is essential

PALLAS trial and ctDNA

Therapy optimization: Endocrine approaches in…

Surgery remains soc in low risk EBC

ALTTO trial outcome according to endocrine therapy

SERDs in early breast cancer - the new era has begun?

Revolution in adjuvant endocrine therapy?

AI based prognostic test

Giredestrant will replace current adjuvant therapy

Safety data DB11

Significant innovations in early and metastatic HER2+…

ctDNA analysis could optimize the approach in HER2+

sTILs with deep learning AI

Quality of live data DB11

In addition to pCR, ctDNA is prognostically relevant…

Olaparib neoadjuvant with high PCR rates

Carboplatin in adjuvant setting of TNBC

Otimização da terapia: abordagens endócrinas em…

Risultati dello studio ALTTO in base alla terapia…

La chirurgia rimane lo standard di cura nei casi di…

Carboplatino nel contesto adiuvante del TNBC

SERDy we wczesnym raku piersi -początek nowej epoki?

Elacestrant is a good combination partner for HR+ HER2+…

Traditional chemotherapy should not be forgotten as…

Phase 2 combination of elacestrant with everolimus or…

No improvement over standard therapy

Chemotherapy-free treatment: a promising therapeutic…

ASCENT-07 a negative trial

Triple-positive MBC: less chemotherapy, more endocrine…

Elacestrant as oral endocrine backbone

Updated results of VIKTORIA-1

Biomarker and clinical subgroup analysis of evERA…

Make a hot tumor out of a cold tumor

Palbociclib likely delays CNS progression

Tucatinib a new SERD in the adjuvant setting

CDK4/6 inhibitor + endocrine therapy remains the…

New evidence for oral SERDs

Maintenance therapy HER2+ Tucatinib as a new option

Significant innovations in early and metastatic HER2+…

Monitoring of ILD

Elacestrant come partner endocrino orale

La dinamica del ctDNA come biomarcatore di risposta

Résultats actualisés de VIKTORIA-1

Sem melhorias em relação à terapia padrão

Risultati aggiornati di VIKTORIA-1

Tucatinib, un nouveau SERD dans le cadre d'un…

Jeszcze nie czas na rezygnację z tradycyjnej…